Differential scanning fluorimetry (DSF) for covalent ligands

Differential scanning fluorimetry (DSF), also known as a thermal shift assay, is one of the most common techniques for fragment screening according to the most recent methods poll on Practical Fragments. This popularity is in part due to the simplicity of the assay: just mix your protein with a dye such as SYPRO Orange, which binds to the hydrophobic core of unfolded proteins, heat the solution in a PCR thermocycler, and measure the change in fluorescence. Ligands that bind specifically to proteins often stabilize them, increasing the melting temperature. As we noted in 2017, some companies even use DSF to assess the ligandability of new targets.

 

Most of the focus on DSF has involved non-covalent ligands. But the approach also works for covalent ligands, according to a new open-access paper in the British Journal of Pharmacology by Nir London and colleagues at the Weizmann Institute of Science.

 

The researchers acknowledge that they are not the first to explore DSF on covalent ligands; last year we discussed a screen of 47 covalent fragments against 47 kinases, and just last month we highlighted a DSF screen that identified an unexpectedly covalent fragment hit.

 

The new paper starts by performing DSF on five drug targets (BTK, the G12C mutant of KRAS, SARS-CoV-2 MPro, Pin1, and Keap1), each with well-characterized covalent ligands (for example, ibrutinib, acalabrutinib, and evobrutinib for BTK, sotorasib and adagrasib for KRAS^G12C, etc.) For four of the proteins they also tested non-covalent or covalent reversible ligands. Almost all of the ligands increased thermal stability of the bound protein, and covalent ligands tended to have a greater effect.

 

In addition to testing specific ligands, the researchers also performed DSF experiments on the five proteins with three reactive, non-specific covalent ligands: iodoacetamide, ethyl 2-(bromomethyl)acrylate, and a chloroacetamide called RA13. Intact protein mass spectrometry confirmed that these molecules gave essentially complete modification of the five proteins, in some cases at multiple sites.

 

In contrast to the specific ligands, the reactive alkylators tended either to have marginal effects on the melting temperatures of the proteins or to actually destabilize the proteins, sometimes dramatically. That said, there were cases of stabilization. The researchers suggest that “reactive, non-specific, irreversible binders may act as destabilizers, since they form an irreversible covalent bond regardless of molecular recognition, which may result in deformation of the protein if the rest of the binder cannot be accommodated near the modified amino acid.”

 

To assess how well DSF works for covalent fragments more generally, the researchers acquired 2612 acrylamides from Enamine and screened them (each at 8 µM in pools of 5) against Keap1 for 24 hours at 4 ºC. Mass spectrometry showed that just over 100 gave at least 50% modification, which a back of the envelope calculation suggests a covalent efficiency roughly 1 M^-1s^-1. Next, 84 compounds with differing degrees of modification were tested by DSF, and, in contrast to the kinase paper we discussed last year, there was a correlation between extent of modification and either stabilization or destabilization of the protein. But consistent with the specific ligands discussed above, the more reactive fragments (as assessed by glutathione reactivity) were the only ones that caused destabilization.

 

The authors conclude by proposing “DSF as a fast and complementary follow-up approach for electrophilic fragment screening, to prioritize productive and selective covalent binders over promiscuous reactive fragments.” This seems reasonable – what do you think?

Fluorine NMR meets make-on-demand libraries

Last month Practical Fragments wrote about make-on-demand libraries, such as those offered by Enamine. We’ve also written about fluorine-detected NMR screening of fragments, which is both rapid and particularly sensitive for low affinity binders. A new paper in ChemMedChem by Patrick Penner, Anna Vulpetti, and colleagues at Novartis combines these two concepts.

 

The researchers had previously built a library of 5472 fluorinated fragments. These were compared with the 77 billion molecules then in Enamine REAL Space, which are based on a smaller set of building blocks that can be combined using validated chemistries. More than a third of the Novartis library members could be found in REAL Space, and nearly 80% had close analogs, supporting the notion that one could do rapid follow-up studies of fragment hits without requiring resource-intensive in-house chemistry.

 

To test whether this would work in practice, the researchers turned to embryonic ectoderm development protein (EED), an oncology target that Novartis has been pursuing for some time; here’s a 2017 post. An undisclosed number of known fragment ligands were screened against Enamine REAL Space using three computational methods: a search of the 180,000+ Enamine building blocks themselves, SpaceMACS to find close analogs, and FastROCS to find more distant analogs.

 

Of 150 compounds ordered across the three categories, 125 arrived: 66 building blocks, 30 close analogs, and 29 distant analogs. All of these were first tested by SPR, and nine (mostly close analogs) showed at least double-digit micromolar binding.

 

To assess whether ¹⁹F NMR could identify weaker binders, the remaining 116 compounds were screened in mixtures of nine each. This led to 43 additional hits, of which several were characterized in more detail by competing them in a dose-response format against a reporter molecule to calculate dissociation constants. One of these came in at sub-micromolar affinity, though it was a close analog of a known binder; the others were high micromolar.

 

Two of the more novel (and less potent) molecules were used as starting points to select new molecules from Enamine REAL space, and 74 of the 81 selected were delivered and tested by SPR or DSF. Two of these were more potent than the starting molecules, one of them by more than an order of magnitude.

 

In the end, although the results are modest, the paper provides a detailed framework for applying fluorine NMR to make-on-demand libraries. And with only four authors, it seems to be a low-effort approach. Although this work was done at Novartis, it should be suitable for smaller companies or academic labs that have access to an NMR.

Fragment events in 2026 and 2027

We're half-way through 2026, but there are still some good events ahead. And 2027 is already starting to take shape.

September 14-16: Fragments X, RSC-BMCS Tenth Fragment-based Drug Discovery Meeting, will be held in the original Cambridge (UK). You can read my impressions of the 2024 meeting, the 2013 meeting, and the 2009 meeting.

September 28 to October 1: CHI’s Twenty-Fourth Annual Discovery on Target will be held as always in brilliant Boston. As the name implies this event is more target-focused than chemistry-focused, but there are always plenty of FBDD-related talks. You can read my impressions of the 2025 meeting, the 2024 meeting, the 2023 meeting, the 2022 meeting, the 2021 meeting, the 2020 virtual meeting, the 2019 meeting, and the 2018 meeting.

 

November 10-12: CHI holds its third Drug Discovery Chemistry Europe in beautiful Barcelona. This will include tracks on lead generation, protein-protein interactions, degraders and glues, and machine learning, with multiple fragment talks throughout. 

2027

April 19-22: CHI’s Drug Discovery Chemistry returns as usual to sunny San Diego, and there are always plenty of fragment talks. You can read impressions of the 2026 meeting, the 2025 meeting, the 2024 meeting, the 2023 meeting, the 2022 meeting, the 2021 virtual meeting, the 2020 virtual meeting, the 2019 meeting, the 2018 meeting, the 2017 meeting, the 2016 meeting; the 2015 meeting here, here, and here; the 2014 meeting here and here; the 2013 meeting here and here; the 2012 meeting; the 2011 meeting; and the 2010 meeting. 

September 19-22: FBLD 2027 will be held for the first time in lovely Lund. This will mark the tenth in an illustrious series of conferences organized by scientists for scientists. You can read impressions of FBLD 2024, FBLD 2018, FBLD 2016, FBLD 2014, FBLD 2012, FBLD 2010, and FBLD 2009. 

Know of anything else? Please leave a comment or drop me a note.